{"id":"reduced-doses-of-anti-tnf","safety":{"commonSideEffects":[{"rate":null,"effect":"Infections (including serious infections)"},{"rate":null,"effect":"Tuberculosis reactivation"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Upper respiratory tract infections"}]},"_chembl":{"chemblId":"CHEMBL3897557","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Anti-TNF drugs (such as infliximab, adalimumab, or etanercept) block tumor necrosis factor-alpha, a key inflammatory cytokine. By using reduced doses, this therapeutic approach aims to balance efficacy in controlling inflammatory diseases with decreased risk of serious infections and other adverse effects associated with TNF inhibition. This strategy is particularly relevant for patients who have achieved disease control and may tolerate lower maintenance doses.","oneSentence":"Reduced doses of anti-TNF agents lower the concentration of tumor necrosis factor inhibitors to minimize immunosuppression while maintaining therapeutic benefit.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:04:22.854Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis (maintenance therapy at reduced dose)"},{"name":"Inflammatory bowel disease (Crohn's disease and ulcerative colitis)"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"}]},"trialDetails":[{"nctId":"NCT04374877","phase":"PHASE1","title":"Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Coherus Oncology, Inc.","startDate":"2020-04-22","conditions":"Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma","enrollment":145},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT03941496","phase":"PHASE1, PHASE2","title":"Azacytidine During Anti-tuberculosis Therapy","status":"WITHDRAWN","sponsor":"Andrew Dinardo","startDate":"2022-10","conditions":"Tuberculosis, Pulmonary","enrollment":""},{"nctId":"NCT03172377","phase":"PHASE4","title":"Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2017-05-03","conditions":"Crohn Disease in Remission, Crohn Disease","enrollment":174},{"nctId":"NCT03351647","phase":"","title":"Predictive Factors of Clinical Response to Ustekinumab in Active Crohn's Disease","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2018-02-14","conditions":"Crohn Disease","enrollment":18},{"nctId":"NCT01881308","phase":"PHASE4","title":"Assessing Withdrawal of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Diakonhjemmet Hospital","startDate":"2013-06-17","conditions":"Rheumatoid Arthritis","enrollment":320},{"nctId":"NCT02065557","phase":"PHASE3","title":"Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-10-13","conditions":"Ulcerative Colitis","enrollment":101},{"nctId":"NCT00686374","phase":"PHASE3","title":"Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2008-05-01","conditions":"Crohn's Disease","enrollment":100},{"nctId":"NCT01276314","phase":"NA","title":"Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2009-01","conditions":"Drug Hypersensitivity","enrollment":135},{"nctId":"NCT01604629","phase":"PHASE4","title":"Evaluation of a Protocol for Dose Reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF","status":"COMPLETED","sponsor":"Spanish Clinical Pharmacology Society","startDate":"2012-07","conditions":"Spondylarthropathies","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Adalimumab: 40 mg / 3 weeks","Etanercept: 50 mg / 10 days","Golimumab: 50 mg / 6 weeks","Infliximab: 3 mg/kg / 8 weeks"],"phase":"marketed","status":"active","brandName":"Reduced doses of anti-TNF","genericName":"Reduced doses of anti-TNF","companyName":"Spanish Clinical Pharmacology Society","companyId":"spanish-clinical-pharmacology-society","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Reduced doses of anti-TNF agents lower the concentration of tumor necrosis factor inhibitors to minimize immunosuppression while maintaining therapeutic benefit. Used for Rheumatoid arthritis (maintenance therapy at reduced dose), Inflammatory bowel disease (Crohn's disease and ulcerative colitis), Ankylosing spondylitis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}